Correction to: Considerations and Caveats in Combating ESKAPE Pathogens against Nosocomial Infections (Advanced Science, (2020), 7, 1, (1901872), 10.1002/advs.201901872)

Adv. Sci. 2019, 7, 1901872 The last paragraph in Section 3 (page 8 of 43) of this article contained some inaccurate information. The corrected text is found here. The sentence starting on line 3 is corrected as follows: Omadacycline was approved by the FDA in 2018 for adult patients with community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible microorganisms, including certain Enterobacteriaceae species.^[94] The sentence starting on line 11 is corrected as follows: The antibiotic is more active than doxycycline against Enterococcus, including vancomycin-resistant E. faecalis or E. faecium, and clinical S. aureus strains including methicillin-resistant and tetracycline-resistant strains.^[98] Reference [98] is corrected as follows: a) A. B. Macone, B. K. Caruso, R. G. Leahy, J. Donatelli, S. Weir, M. P. Draper, S. K. Tanaka, S. B. Levy, Antimicrob. Agents Chemother. 2014, 58, 1127; b) A. C. Fluit, S. van Gorkum, J. Vlooswijk, Diagn. Microbiol. Infect. Dis. 2019, 94, 78. The authors apologize for any misunderstanding this error may have caused.